In this study we propose a rationale for the increase of MCT2 expression through an integrative analysis of epigenetic, transcriptome and protein level data from prostate cancer tissue and unveil a link between SLC16A7/MCT2 and major oncogenic pathways in prostate cancer. The gene discussed is SLC16A7; the disease is Familial prostate cancer.